Skip to main content
. 2015 Dec 9;7(3):3520–3532. doi: 10.18632/oncotarget.6513

Figure 4. Proteasome and NAE inhibitors increased the anti-lymphoma effect of RI-BPI.

Figure 4

A. Effect of RI-BPI on pro-apoptotic BCL2-family members in the RI-BPI sensitive GCB-DLBCL SU-DHL6, OCI-Ly1, OCI-Ly7, SC-1 and DoHH2 cells treated for 6 and 12 hours compared to their respective controls (full line, 0 h). Dotted line represents 2-fold expression increase. B. Effect on BIM protein levels at 48 h after exposure to RI-BPI. C. Effect on NOXA protein levels at 24 h after exposure to bortezomib (Bo) and MLN4924 (ML) vs. vehicle (Veh) in SU-DHL6 and OCI-Ly1 cell lines. D. GI50 for bortezomib and MLN4924 (Y-axes) plotted against GI50 for RI-BPI (X-axes) in BCL6-dependent GCB-DLBCL cells. Dotted lines segregated resistant and sensitive cell lines. E. Fold drug reduction (expressed as dose reduction index) for MLN4924 and bortezomib in 8 BCL6-dependent GCB-DLBCL cell lines pre-treated with RI-BPI. Dose reduction indexes greater than 1 represent favorable combinations.